News Center

Home page

Peak Report

News reports

Announcement on the progress of entrusted financial management

Release time:

2020-08-05

证券简称：尖峰集团证券代码：600668 编号：临2019-020

债券简称：13尖峰02 债券代码：122344

浙江尖峰集团股份有限公司

关于委托理财进展情况的公告

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。

重要内容提示：

l 委托理财受托方：广发银行股份有限公司金华分行

l 委托理财金额：10000万元人民币

l 委托理财投资类型：保本浮动收益型结构性存款

l 委托理财期限：2019年5月9日—2019年11月11日

一、本次委托理财概述

（一）本次委托理财的基本情况

公司于2019年5月9日与广发银行股份有限公司金华分行（以下简称“广发银行金华分行”）签署《广发银行“薪加薪16号”人民币结构性存款合同》，公司出资10,000万元人民币购买广发银行金华分行发售的人民币结构性存款XJXCKJ7586号产品，产品期限186天，预期年化收益率4.25%，本产品为保本浮动收益型产品。

公司本次投资委托理财产品的资金为运营中暂时闲置的自有资金，进行短期委托理财，能提高资金使用效率。本次委托理财不构成关联交易。

（二）公司内部需履行的审批程序。

2019年4月26日，公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长决定委托理财的议案》。授权公司董事长行使不超过人民币5亿元的委托理财的决策权，在该额度内资金可以滚动使用，但任一时点存续的委托理财余额合计不得超过5亿元，每笔委托理财的期限均不得超过12个月。详见本公司在2019年4月30日在上海证券交易所网站披露的《关于授权公司董事长利用自有资金进行委托理财的公告》（临2019-012）。

公司本次购买广发银行金华分行发售的单位结构性存款XJXCKJ7586理财产品，在公司第十届董事会第10次会议授权董事长决策范围之内。

二、本次委托理财协议主体的基本情况

（一）交易对方名称：广发银行股份有限公司金华分行，公司类型：股份有限公司分公司（国有控股），营业场所：浙江省金华市婺城区八一南街999号赞佳大厦主楼1-4层、裙楼2-3层及4层局部，负责人：李振岳，经营范围：经营中国银行业监督管理委员会依照有关法律、行政法规和其他规定批准的业务，经营范围以批准文件所列的为准。（依法须经批准的项目，经相关部门批准后方可开展经营活动）

（二）广发银行股份有限公司金华分行与本公司之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。

三、本次委托理财合同的主要内容

（一）基本说明

公司本次购买理财产品的资金来源为公司自有资金，委托理财期限为 2019年5月9日至2019年11月11日，该产品为保本浮动收益型结构性存款产品，预期年化收益率为2.6%或4.25%，无需提供履约担保。银行和投资者应各自承担其在本合同项下应交纳的税费。本产品收益的计算中已包含（计入）银行的运营管理成本（如账户监管、资金运作管理、交易手续费等），公司无需支付或承担本产品下的其他费用或收费。

（二）产品说明

1、投资方向及受益权比例

本结构性存款所募集的资金本金部分纳入广发银行金华分行资金统一运作管理，投资于货币市场工具（包括但不限于银行存款、拆借、回购等）的比例区间为20%-100%、债券（包括但不限于国债、央票、金融债、短期融资券、企业债、中期票据、公司债）等金融资产的比例区间为0%-80%，收益部分投资于与美元兑港币的汇率水平挂钩的金融衍生产品，投资者的结构性存款收益取决于美元兑港币的汇率在观察期间内的表现。

2、收益计算

结构性存款收益率与美元兑港币的最终汇率水平挂钩。美元兑港币的最终汇率是指2019年05月20日路透页面香港时间上午11：30“ HKDFIX”公布的美元兑港币汇率。如果届时约定的数据提供商路透资讯（Reuters）页面不能给出适用的价格水平，或者用于价格水平确定的版面或时间发生变化，广发银行将本着公平、公正、公允的原则，选择市场认可的合理的价格水平进行计算。

汇率区间为（7.0000, 9.0000），即汇率区间下限为7.0000，汇率区间上限为9.0000。

结构性存款收益说明：

（1）如果美元兑港币的最终汇率始终位于汇率区间内（不含边界点），则到期时结构性存款收益率为4.25％（年化收益率）；

（2）如果美元兑港币的最终汇率始终位于汇率区间外（含边界点），则到期时结构性存款收益率为2.6％（年化收益率）。

结构性存款收益情景模拟：

	观察日美元兑港币的最终汇率P	年化收益率
情景一	P≥9.0000 或 P≤7.0000	2.6%
情景二	7.0000<P<9.0000	4.25%

投资者获得的结构性存款收益=结构性存款本金×到期年化收益率×实际结构性存款天数÷365，精确到小数点后2位。

3、提前终止：

本结构性存款存续期内，结构性存款投资者无提前终止权利。

4、提前赎回：

本结构性存款投资期间不设提前赎回，结构性存款投资者无提前赎回该结构性存款的权利。

5、本金及收益兑付：

本结构性存款成立且投资者持有该结构性存款直至到期日，则广发银行在结构性存款到期日向投资者偿付全部人民币本金，并按照规定向投资者支付结构性存款收益。

6、产品特点

（1）本金安全，提供博取更高收益的机会：在持有到期的情况下产品可以保证投资者本金不受损失。

（2）指标客观，结构简单：本结构性存款的收益与美元兑港币的汇率水平挂钩。

（三）敏感性分析

公司本次以自有资金10，000万元购买的广发银行金华分行结构性存款XJXCKJ7586号产品期限较短，不会对公司生产经营状况造成影响。在该投资期限内减少公司现金流净额10，000万元，到期后预期为公司产生收益216.58万元。

（四）风险控制分析

本产品为保本浮动收益型产品，银行确保公司本金安全，符合公司维护全体股东和公司利益的原则。公司始终将委托理财产品风险防控工作放在首位，严格按照内控制度有关规定，投资委托理财产品均为期限短、安全性高、流动性好的低风险银行理财产品。公司对购买的理财产品严格把关，谨慎决策。

（五）独立董事意见

公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长利用自有资金进行委托理财的议案》，独立董事发表了独立意见，认为：公司委托理财是在确保公司日常运营和资金安全的前提下实施的，不影响公司日常资金周转，不影响公司经营业务的正常开展。通过进行适度的低风险的理财产品投资业务，可以提高资金使用效率，能获得一定的投资效益，为公司股东谋取更多的投资回报。未发现有损害公司及中小股东权益的情形。同意授权董事长利用自有资金进行委托理财。

四、公司累计进行的委托理财情况

公司曾于2019年1月31日，在《上海证券报》、《中国证券报》及上海证券交易所网站上披露了《关于委托理财进展情况的公告》。截至本公告日，公司已经收回了全部到期的委托理财。

前次进展公告后，截至本公告日，公司累计进行委托理财的金额为4亿元。详见下表：

序号

受托人

理财产品类型

金额

（万元）

起始日

到期日

截止公告日已收回本金金额（万元）

截止公告日获得收益（万元）

交通银行金华分行

蕴通财富定期型结构性存款

3,000.00

2019/2/1

2019/6/6

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页